



## LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

9457-023

APPLICATION NO.

09/873,234

APPLICANT

Palazzini and Gambaro

FILING DATE

June 4, 2001

GROUP

TBA

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
PL	AA	5,733,566	3/31/98	Lewis			
PL	AB	5,674,533	10/7/97	Santus et al.			
PL	AC	5,639,476	6/17/97	Oshlack et al.			
PL	AD	5,591,767	1/7/97	Mohr et al.			
PL	AE	5,496,807	3/5/96	Marchi and Tamagnone			
PL	AF	5,354,556	10/11/94	Sparks and Geoghegan			
PL	AG	5,236,910	8/17/93	Egidio and Gianfranco			
PL	AH	5,120,548	6/9/92	McClelland and Zentner			
PL	AI	5,073,543	12/17/91	Marshall et al.			
PL	AJ	5,059,595	10/22/91	Le Grazie			
PL	AK	4,008,719	2/22/77	Theeuwes and Ayer			
PL	AL	3,936,351	2/3/76	Bianchini			
PL	AM	3,916,899	11/4/75	Theeuwes and Higuchi			
PL	AN	3,845,770	11/5/74	Theeuwes and Higuchi			
PL	AO	3,598,123	8/10/71	Zaffaroni			
PL	AP	3,536,809	10/27/70	Applezweig			

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
PL	AQ	EP 0513513	8/7/96	EP				

## OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

PL	AR	Ansel H.C., <u>Introduction to Pharmaceutical Dosage Forms</u> , Lea and Febiger, Philadelphia, PA (1985) (Table of Contents)
PL	AS	Baggio B. et al., "Urinary Glycosaminoglycans, Sialic Acid and Lysosomal Enzymes Increase in Nonalbuminuric Diabetic Patients", <u>Nephron</u> 43:187-190 (1986)
PL	AT	Callas D.D. et al., "Comparative Pharmacologic Profile of a Glycosaminoglycan Mixture, Sulodexide, and a Chemically Modified Heparin Derivative, Suleparoid", <u>Sem. Thromb. Hemost.</u> 19 (Suppl. 1):49-57 (1993)
PL	AU	Caulfield J.P. et al., "Loss of Anionic Sites from the Glomerular Basement Membrane in Aminonucleoside Nephrosis", <u>Lab. Invest.</u> 39:505-512 (1978)
PL	AV	Cospite M. et al., "Haemodynamic Effects of Sulodexide in Post-Thrombophlebitic Syndromes", <u>Acta Therapeutica</u> 18:149-159 (1992)
PL	AW	Crepaldi G. et al., "Double-Blind Multicenter Trial on a New Medium Molecular Weight Glycosaminoglycan. Current Therapeutic Effects and Perspectives for Clinical Use", <u>Atherosclerosis</u> 81:233-243 (1990)



		Dedov I. et al., "A Randomized, Controlled Study of Sulodexide Therapy for the Treatment of Diabetic Nephropathy", Nephrol. Dial. Transplant <u>12</u> :2295-2300 (1997)
PL	AY	Diamond J.R. and Karnovsky M., "Nonanticoagulant Protective Effect of Heparin in Chronic Aminonucleotide Nephrosis", Renal Physiol. <u>9</u> :366-374 (1986)
PL	AZ	Ebert, "Soft Elastic Gelatin Capsule", Pharm. Tech, <u>1</u> (5):44-50 (1977)
PL	BA	Gambaro G. and Van Der Woude J., "Glycosaminoglycans: Use in Treatment of Diabetic Nephropathy", Am. Soc. Nephrol. <u>11</u> :359-368 (2000)
PL	BB	Gambaro G. et al., "Glycosaminoglycans Prevent Morphological Renal Alterations and Albuminuria in Diabetic Rats", Kidney Int. <u>42</u> :285-291 (1992)
PL	BC	Goldman L. and Claude Bennett J (editors), Cecil Textbook of Medicine (pages 1281-1283), 21st Edition (2000), W.B. Saunders, Philadelphia
PL	BD	Groggel G.C. et al., "Changes in Heparin Sulfate Correlate with Increased Glomerular Permeability", Kidney Int. <u>33</u> :517-523 (1988)
PL	BE	Harenberg J, "Review of Pharmacodynamics, Pharmacokinetics, and Therapeutic Properties of Sulodexide", Medicinal Research Rev. <u>18</u> :1-20 (1998)
PL	BF	Kanwar Y.S. et al., "Basement Membrane Proteoglycans of the Kidney", Sem. Nephrol. <u>5</u> :307-313 (1985)
PL	BG	Parthasarathy N. and Spiro, R., "Effect of Diabetes on the Glycosaminoglycan Component of the Human Glomerular Basement Membrane", Diabetes <u>31</u> :738-741 (1982)
PL	BH	Poplawska A. et al., "Effect of Glycosaminoglycans on Urinary Albumin Excretion in Insulin-Dependent Diabetic Patients with Micro- or Macroalbuminuria", Diabetes Res Clin. Pract. <u>38</u> :109-114 (1997)
PL	BI	Purkerson, M. et al., "N-Desulfated/Acetylated Heparin Ameliorates the Progression of Renal Disease in Rats with Subtotal Renal Ablation", J. Clin. Invest. <u>81</u> :69-74 (1988)
PL	BJ	Radhakrishnamurthy B. et al., "Studies of Glycosaminoglycan Composition and Biologic Activity of Vessel®, a Hypolipidemic Agent", Atherosclerosis <u>31</u> :217-229 (1978)
PL	BK	Remington's Pharmaceutical Sciences, 1995, Mack Publ. Co., Easton, PA. (Table of Contents)
PL	BL	Salvetti A. et al., "Renal Protection and Antihypertensive Drugs", Drugs <u>57</u> :665-693 (1999)
PL	BM	Škrha J. et al., "Glycosaminoglycan Sulodexide Decreases Albuminuria in Diabetic Patients", Diabetes Res. Clin. Pract. <u>38</u> :25-51 (1997)
PL	BN	Solini A. et al., "Therapy with Glycosaminoglycans Lowers Albumin Excretion Rate in Non-Insulin Dependent Diabetic Patients with Macroalbuminuria", Diabetes Nutr. Metab. <u>7</u> :304-307 (1994)
PL	BO	Sozzi C., "The Preventive Activity of an Extractive Glycosaminoglycane (Sulodexide) in Relapses of TIA. A Short Term Study", Eur. Rev. Med. Pharmacol. Sci. <u>6</u> :295-300 (1984)
PL	BP	Szelanowska M. et al., "A Pilot Study of the Effect of the Glycosaminoglycan Sulodexide on Microalbuminuria in Type I Diabetic Patients", Curr. Med. Res. Opin. <u>13</u> :539-545 (1997)
PL	BQ	Thomas D.P. et al., "Relative Efficacy of Heparin and Related Glycosaminoglycans as Antithrombic Drugs", Ann. N.Y. Acad. Sci. <u>556</u> :313-322 (1989)

EXAMINER

DATE CONSIDERED

 PL  
~~5-29-902~~ 4-29-02

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.